N@N

Seattle Genetics to Present at the J.P. Morgan Healthcare Conference

^{Published on 2009-01-06 07:02:43, Last Modified on 2009-01-06 07:03:09 - Market Wire}
 

BOTHELL, Wash.--([ BUSINESS WIRE ])--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 27^th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2009, at 3:00 p.m. Pacific Time. A live webcast of the presentation will be available from Seattle Genetics' website, [ www.seattlegenetics.com ], under the "News and Investor Information" section. The conference is being held at the Westin St. Francis Hotel in San Francisco, California.

About Seattle Genetics

Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company has four product candidates in ongoing clinical trials: dacetuzumab (SGN-40), lintuzumab (SGN-33), SGN-35 and SGN-70. Dacetuzumab is being developed under a worldwide collaboration with Genentech. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics, Daiichi Sankyo and MedImmune, a subsidiary of AstraZeneca, as well as an ADC co-development agreement with Agensys, a subsidiary of Astellas Pharma. More information can be found at [ www.seattlegenetics.com ].